Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-(L)1 plus lobaplatin vs cisplatin/carboplatin chemotherapy in first-line advanced driver-negative NSCLC
ChiCTR2400079707Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lobaplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: progression-free survival. Started Jan 2024; status: recruiting.
02
Drugs
lobaplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400079707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079707.